TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adherence (Visual Analogue Scale)
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Quality of life measured by St. George's Respiratory Questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disability of Arm, Shoulder and Hand (DASH) scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delay in development of end-stage renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lung parenchymal hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary tumor control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dysphagia symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dark trough value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Light/dark (Arden) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with 2-grade Reduction in IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Planned ablation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of expanded NK cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of ritonavir and saquinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bystander Cardiopulmonary Resuscitation (CPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Objective Opioid Withdrawal Score (OOWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in mood disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects Reporting Serious Adverse Events (SAEs) From Day 0 up to Month 7
Endpoint domain: Adverse events/effects
Primary endpoint: HIV Viral Load in All HIV+ Subjects at Month 10 and Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of Elvitegravir (EVG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Tenofovir Alafenamide (TAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of risk of pulmonary aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effectiveness of ablation of non-metastatic renal tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Mood Disturbances
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of a final diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of stenosis in Melody valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: grade of regurgitation in Melody valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of necessary re-interventions of Melody valve
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initiation of the HPV Vaccine 2-dose Series
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of the HPV Vaccine 2-dose Series
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of meal-induced tLESr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of days in the ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of days on Hemolung therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Outcome at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of the Apoptotic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving PASI 50 score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Depression/Anxiety Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total composite events of cardiovascular death or new or worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of cardiovascular death, new or worsening heart failure, recurrent myocardial infarction, or stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sputum direct smear positive for acid-fast bacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in mean Atopic Dermatitis Severity Index (ADSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiographic Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum mouth opening pain free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Health-related quality of life (HRQoL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Locomotor capabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unduplicated palliative care patients screened for spiritual concerns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and type of spiritual issues identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of referrals to the chaplain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of the fasting mimicking diet
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Fasting Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of anal fistula patients treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total score change from baseline at 4 weeks post-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clotting and Bleeding Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the plasma concentration time profile over the steady-state dosing interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic clearance (Cl/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating naive and memory T cell count (CD45RA/CD45RO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating regulatory T cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Compliance rate for completion of neuropsychological and behavioral battery
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: PTSD Checklist-Civilian version (PCL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-Reported Outcomes Measurement Information System (PROMIS) - Sleep Disturbance Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of participants losing and maintaining clinically significant body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: wavefront aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed perfusion rest score (SPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Challenging Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 12-month progression-free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of constructed space maintainers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of blood perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Protocol compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Left Ventricular End Diastolic Volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin conductance level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite rate of major- and minor vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in Maximum Cystometric Bladder Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of carbon nanoparticle labelled lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coma Recovery Scale-Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants with D- deficiency or access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fecal occult blood test (FOBT) uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sleep disordered breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Area under the Concentration - Time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of GFR (glomerular filtration rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline measure of Dual Task Cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of endometrial aspiration biopsy and D&C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical parameters measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of a running-related injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak loading (N/s) during running and jumping movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of loading (N/s2) during running
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Outcome as measured by visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Outcome as measured by Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Outcome as measured by Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) - patellofemoral scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in perceptions of chemotherapy-induced peripheral neuropathy (CIPN)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of neurologic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Musculoskeletal injury incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of participants reporting treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Level of spectrin breakdown product-145 (SBDP-145)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of Care-giving inventory (ECI)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Carer Wel-Being & Support (CWS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HCC diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of correctly inserted UVC at optimum catheter tip position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to PSA Progression (TTPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Composite of acute ischemic stroke, TIA, myocardial infarction, or death from vascular causes
Endpoint domain: Mortality/survival
Primary endpoint: Bleeding events as defined by BARC criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Areas of the brain with low activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline of the Local PSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Without Grade ≥ 3 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Intra-operative Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acoustic rhinometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Application of Objective Neuromuscular Monitoring in Depolarizing NMBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Application of Objective Neuromuscular Monitoring in Non-depolarizing NMBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with a PASI score reduction higher than 75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach a reduction in the PASI score higher than 75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor necrosis factor alpha (TNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin 6 (IL6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients discussing CAM use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose (MTD) or maximum administered dose (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with supracondylar femoral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinically Significant Improvement in the Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of Breathing Rate Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of thromboelastogram parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Change in neuropsychological measures of executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Change in expressive language
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of change in learning and memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: radiographic defect area by cone beam x ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic bone density by cone beam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth outcomes in offspring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental functioning in babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily allergy severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative flow volume (LSFG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D volumetric elasticity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Miller Social Intimacy Scale (MSIS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Knowledge of HIV serostatus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CO sample of ≤ 4ppm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant reporting not smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects with Diagnosis of Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Alteration of AMH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum drug levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-drug antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (Serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of acute care utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With Symptomatic, Lab-confirmed COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in appearance of facial redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in appearance of facial pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of immunizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non-inferiority of anti-HPV 16 and 18 seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Persistent infection of HPV31, 33, 45, 52 and 58
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of CIN2 + and/or VIN2 + and/or VaIN2 + lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects With a Positive Glucose Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart failure status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in abdomen area appearance assessed by 3D Photographic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in abdomen area appearance assessed by Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between the two procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurophysiological measures changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titer 30 Days After the Last Study Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroconversion 30 Days After the Last Study Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower incidence of SSI due to timing
Endpoint domain: Adverse events/effects
Primary endpoint: Lower incidence of SSI due to dose adjustments
Endpoint domain: Adverse events/effects
Primary endpoint: Lower incidence of SSI due to redosing
Endpoint domain: Adverse events/effects
Primary endpoint: surface markers of T cell as assessed by FACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immune parameters to be assessed by western including STAT proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Non-Alcoholic Fatty Liver Disease (NAFLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in child self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in caregiver reported adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in child reported adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status